This can occur in patients with a concealed pathway and often it is initiated by an APC
These findings highlight the capacity of GLP-1RAs to extend their therapeutic impact well beyond traditional metabolic targets
Tirzepatide (Zepbound), a dual GLP-1/GIP receptor agonist, is also approved for weight management, though evidence in post-bariatric populations is still emerging
Use a marked water bottle, a tracking app, or a simple tally system
ber die jeweilige Marken-Seite kommst du direkt zum kompletten Angebot des Herstellers
The risk of lean mass loss during rapid weight reduction on tirzepatide is a particular concern for autoimmune patients who may already have muscle wasting from disease activity, corticosteroid use, or reduced physical activity during flares